Novo Nordisk Slashes Ozempic and Wegovy Prices by 50%

Novo's full-year 2025 results, reported February 4, 2026, showed sales growth of 10% at constant exchange rates to DKK 309.1 billion, with Q4 revenue of DKK 79.14 billion and Q4 earnings of DKK 26.89 billion. Net income for the year totaled DKK 102.4 billion. The stock fell 14% on earnings day despite a modest EPS beat ($1.02 vs. $0.92 expected) because the company guided for 2026 adjusted sales down 5% to 13% at CER — which would mark the first annual sales decline since 2017 — and operating profit down as much as 13%. The guidance factors in the loss of exclusivity for semaglutide in certain international markets and the absence of favorable U.S. gross-to-net adjustments that flattered 2025.

The analyst community has calibrated accordingly. Goldman Sachs downgraded Novo to Neutral on March 2 and cut its price target from $63 to $41. Citigroup's April note cut its target on the Danish-listed shares to DKK 275 while maintaining Neutral. Argus sits at Hold. The consensus 1-year target of $46.54 implies roughly 19% upside from here — meaningful, but nothing like the recovery multiples that were being thrown around twelve months ago. Jyske Bank analyst Henrik Hallengreen Laustsen summarized the mood bluntly in late February: "Confidence in the share is at rock bottom." That was before two more downgrades.

Yet the one-month move — up 7.2% while Lilly was up just 1.6% — suggests something is shifting at the margin. The selling exhaustion that typically marks capitulation shows up in volume patterns, insider buying, and analyst dispersion. Novo hit its 52-week low of $35.12 in late March. Two of the three catalysts that have emerged since (Amazon disruption, Medicare confirmation, etavopivat Phase III) were nominally bearish at first read but structurally support a volume-recovery thesis. The tape is starting to agree.

Lilly's advantages are structural. The Indianapolis-based company fields eight blockbuster drugs generating over $1 billion annually, spanning oncology, immunology, and gene therapy alongside its diabetes and obesity portfolio. In April 2026 Lilly announced the acquisition of Kelonia Therapeutics for up to $7 billion, further diversifying its cancer and gene-therapy pipeline, and on April 21 received FDA approval for Foundayo — the first oral GLP-1 pill. Novo, by contrast, relies on six blockbusters concentrated overwhelmingly in metabolic disease. Its two largest drugs accounted for roughly 67% of total sales in 2025, versus 56% for Lilly's top two — a concentration risk that's central to the discount investors now demand.

Lilly has not yet matched Novo's commercial list-price cuts. Zepbound and Mounjaro carry higher list prices, which gives Lilly room to respond strategically — or to hold prices and protect margins while volume remains favorable. Lilly's guidance is for continued 2026 growth; its forward P/E of 26.74 and PEG of 1.33 reflect that expectation. The market's willingness to pay forty times earnings for Lilly and ten times earnings for Novo prices in near-flawless execution at the former and continued multiple compression at the latter. That asymmetry is the trade question: are those two outcomes as certain as the multiples imply?

A more nuanced read: Lilly is the better business, but the better business at four times the price is not automatically the better stock. Lilly's PEG of 1.33 says the market is fairly paying for growth. Novo's 10.8x P/E with a potential single-year sales decline already baked in says the market is fairly paying for stagnation — or the early innings of a rare-disease pivot the sell-side hasn't modeled yet.

The single most important event for Novo since the February price cut did not come from a regulator, a competitor, or the company itself — it came from Seattle. On April 21, 2026, Amazon launched a bundled GLP-1 program through One Medical combining screening, prescription, monitoring, and Amazon Pharmacy delivery. The entry price: $25 per month with insurance, $149 per month direct-pay for oral Wegovy or Lilly's Foundayo. Same-day delivery is being expanded to 4,500 cities by year-end. Shares of both Novo and Lilly fell on the news.

The first-order read is that Amazon is a margin vampire. The second-order read is that it is solving Novo's biggest problem. Novo's 2026 sales guidance assumes ~5-13% decline driven by list-price erosion and commercial channel leakage. An integrated consumer channel that routes millions of cash-paying and insured patients through a single digital front door compresses customer-acquisition costs, shrinks the gray market that compounders exploit, and routes volume directly to branded Wegovy rather than unregulated compounded semaglutide. The shift from "list price minus rebate minus coupon" to "Amazon retail price" is a simplification of Novo's economics, not just a compression.

The Medicare GLP-1 Bridge completes the architecture. From July 1, 2026 through December 31, 2027, Medicare Part D beneficiaries meeting eligibility criteria pay a $50 monthly copay for Wegovy, Ozempic, Rybelsus, Zepbound, and Foundayo. CMS has already confirmed the program's parameters in March 2026 guidance, and on April 21 announced it will be extended through 2027 (with the BALANCE Model deferred). The eligible Medicare population runs into tens of millions. Previously excluded from weight-loss coverage, these patients now have a subsidized on-ramp. Net-net pricing per prescription falls. Volume per eligible patient rises. Total category revenue expands.

Novo sits at the choke point of both shifts. Wegovy is the only competitor to Zepbound on the Medicare Bridge formulary — its share of Medicare-covered GLP-1 volume should roughly mirror its share of the commercial market (roughly 40%) at a structurally stable price point of $274 negotiated by CMS. Amazon's delivery network mechanically broadens access to rural, time-constrained, and under-insured patients who currently self-select out of branded GLP-1 use. The $25-with-insurance price point is within roughly 15% of what patients pay for ACA-subsidized generic blood-pressure medicines. That is a category-defining shift in affordability.

The analyst reflex to sell on Amazon's entry is backward-looking. Amazon sold a trillion dollars of merchandise in 2025 not because it captured the margin from its suppliers but because it expanded the aggregate category. Apply the same framework to GLP-1: a $1,000-per-month drug sold by specialty pharmacies becomes a $25-per-month drug sold by Amazon, and the number of patients willing to stay on therapy — the single most important commercial metric for a chronic drug — goes up, not down. That arithmetic does not require Novo to win at Lilly's expense. It requires the category to keep growing.

On April 20, 2026 — the day before Amazon's announcement — Novo Nordisk reported topline Phase III results from the HIBISCUS trial of once-daily oral etavopivat in adolescents and adults with sickle cell disease. The drug met both co-primary endpoints versus placebo: a 27% reduction in annualized vaso-occlusive crises and a statistically significant improvement in hemoglobin response. The median time to first VOC was 38.4 weeks on etavopivat versus 20.9 weeks on placebo — effectively doubling the crisis-free window. Novo plans a late-2026 regulatory filing. The drug carries Orphan Drug designation in both the U.S. and EU and multiple FDA special designations.

To understand how underappreciated this is, note the immediate reaction: Agios Pharmaceuticals, whose mitapivat targets the same PKR-activator mechanism, fell 23% on April 21. The market quickly understood etavopivat is a best-in-class sickle-cell therapy. Novo's stock barely moved on the news, because the GLP-1 narrative is so dominant that a successful Phase III in a $5-billion-plus rare-disease market registered as a sideshow. It isn't.

Sickle cell disease is a historically under-served genetic disorder with approximately 100,000 U.S. patients and roughly 4 million globally. Existing therapies — hydroxyurea, voxelotor (Oxbryta was withdrawn in 2024), crizanlizumab — are either decades old, recently delisted, or limited by side-effect profiles. An oral, once-daily PKR activator with a 27% VOC reduction and durable hemoglobin effect is the most differentiated entry in sickle cell in a generation. Peak-sales estimates for the category, if etavopivat captures a meaningful share, run into the low single-digit billions of dollars annually at pricing consistent with rare-disease precedent.

The strategic implication is larger than the revenue contribution. Novo has been valued as a pure-play GLP-1 company, with the associated concentration discount. Etavopivat is the first major non-metabolic asset in Novo's pipeline to reach Phase III success, and the company has seven rare-disease and rare-blood-disorder programs behind it. If Novo re-rates from "GLP-1 incumbent at risk" to "diversified specialty pharma with GLP-1 and rare-disease franchises," the multiple gap versus Lilly compresses even if the GLP-1 franchise does nothing more than hold 40% market share.

Here is the under-priced observation: at a 10.8x P/E, buyers of NVO are getting the GLP-1 business priced for structural decline and the rare-disease pipeline for free. That is the definition of optionality. If etavopivat is approved and launches in 2027-2028, the cash-flow contribution is immediate and high-margin. If the pipeline produces a second non-metabolic success over the next 24 months, the sell-side will have to reclassify the stock. The base case — semaglutide defends share at a re-architected price — does not need the pipeline to work. Every additional success is pure upside on a depressed cost basis.

The bearish counterargument is formidable. Analyst estimates for 2027 project quarterly EPS modestly above 2025 levels — suggesting limited earnings growth at best, and potentially declining earnings if pricing pressure accelerates faster than volume growth. With the company guiding for its first sales decline in nearly a decade and CagriSema's trial results disappointing, the pipeline catalyst that bulls had counted on is materially weakened. Citigroup's DKK 275 target on the Danish shares implies the stock is fairly valued here. Goldman's $41 target says modest upside. Neither sees a path back to the old highs.

The bullish read that the sell-side is missing: at a 10.8x P/E on trailing earnings, the stock prices in continued share loss, continued price compression, and a pipeline that produces nothing material for the next three years. The triple-discount is the mispricing. Amazon's distribution rail and Medicare's price-setting backstop, taken together, widen the category rather than shrink Novo's slice. Etavopivat's Phase III success is a de-risking event that the sell-side has not rebalanced into the model. If any one of these variables surprises to the upside — Medicare uptake, etavopivat approval, GLP-1 share stabilization at 40% — earnings in 2027-2028 could comfortably exceed current estimates.

Bottom line: this is not a table-pounding buy. It is a setup where the base case is flat and the left tail has already been priced. At 10.8x P/E with a 4.6% dividend yield, investors are being paid to wait while three distinct catalysts — distribution, coverage, pipeline — resolve. The asymmetry is the trade.